Open AccessSomatostatin receptor‐1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer
Author(s) -
Li Min,
Wang Xiaochi,
Li Wei,
Li Fei,
Yang Hui,
Wang Hao,
Brunicardi F. Charles,
Chen Changyi,
Yao Qizhi,
Fisher William E.
Publication year - 2008
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2008.00940.x
Subject(s) - pancreatic cancer , somatostatin receptor , cell cycle , cell growth , cancer research , somatostatin , cancer , endocrinology , cancer cell , medicine , transfection , somatostatin receptor 2 , cell cycle checkpoint , chemistry , biology , cell culture , biochemistry , genetics
Functional somatostatin receptors (SSTR) are lost in human pancreatic cancer. Transfection of SSTR‐1 inhibited pancreatic cancer cell proliferation in vitro . We hypothesize that stable transfection of SSTR‐1 may inhibit pancreatic cancer growth in vivo possibly through cell cycle arrest. In this study, we examined the expression of SSTR‐1 mRNA in human pancreatic cancer tissue specimens, and investigated the effect of SSTR‐1 overexpression on cell proliferation, cell cycle, and tumor growth in a subcutaneous nude mouse model. We found that SSTR‐1 mRNA was downregulated in the majority of pancreatic cancer tissue specimens. Transfection of SSTR‐1 caused cell cycle arrest at the G 0 /G 1 growth phase, with a corresponding decline of cells in the S (mitotic) phase. The overexpression of SSTR‐1 significantly inhibited subcutaneous tumor size by 71% and 43% ( n = 5, P < 0.05, Student's t‐ test), and inhibited tumor weight by 69% and 47% ( n = 5, P < 0.05, Student's t‐ test), in Panc‐SSTR‐1 and MIA‐SSTR‐1 groups, respectively, indicating the potent inhibitory effect of SSTR‐1 on pancreatic cancer growth. Our data demonstrate that overexpression of SSTR‐1 significantly inhibits pancreatic cancer growth possibly through cell cycle arrest. This study suggests that gene therapy with SSTR‐1 may be a potential adjuvant treatment for pancreatic cancer. ( Cancer Sci 2008; 99: 2218–2223)